ArticleFrontiers in cardiovascular medicine2026
Clinical characteristics and predictors of adverse outcomes in children with acute rheumatic fever from a high-endemic region of Brazil.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute rheumatic fever (ARF) remains a leading cause of pediatric cardiovascular morbidity and a major driver of rheumatic heart disease (RHD) in low- and middle-income countries. Early identification of children at highest risk for adverse outcomes is essential to guide timely management and referral, but remains challenging in resource-limited settings. This study aimed to characterize the clinical profile of pediatric ARF and identify readily available predictors of adverse outcomes in a high-endemic region of Brazil. Methods: We conducted a cohort study of children treated for ARF at a tertiary pediatric center in Feira de Santana, Brazil, between 2010 and 2023, including both retrospectively identified cases and a prospectively enrolled subset through the Acute Rheumatic Fever Diagnosis Collaborative (ARC) Network. Clinical, laboratory, treatment, and outcome data were obtained from hospital and outpatient records. The primary outcome was a composite of cardiac surgery or death. Independent predictors were identified using multivariable logistic regression with covariate selection based on clinical relevance and model parsimony. Model performance was assessed using discrimination (C-statistic) and risk reclassification metrics. Results: A total of 151 children were included (median age, 9 years; 46% female). Carditis was present in 76%, with moderate-to-severe involvement in 49%, predominantly affecting the mitral valve. During a median follow-up of 17.5 months, 20 children (13%) experienced the primary outcome. In multivariable analysis, absence of fever (OR 0.14, 95% CI 0.31-0.65), higher ESR (OR 1.04 per mm/h, 95% CI 1.01-1.07), and lower hematocrit (OR 0.85, 95% CI 0.74-0.98) were independently associated with adverse outcomes. Incorporating erythrocyte sedimentation rate (ESR) into the model improved risk prediction, with a net reclassification improvement (NRI) of 0.79 ( Conclusions: In children with ARF, simple inflammatory and hematologic markers are independently associated with progression to severe outcomes. ESR, an inexpensive and widely accessible test, provides incremental prognostic information and may support scalable risk stratification strategies aimed at reducing progression to advanced RHD in resource-limited endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.